 Context Therapeutics NASDAQ:CNTX Inc has indicated in its corporate guidance for 2023 that with ample cash on hand, the company has the scope to advance its pipeline programs. As of September 30, 2022, the Philadelphia-based womens oncology company developing treatments for breast and gynecological cancers, had cash, and equivalents which totaled 39.4 million. 